LOCALLY RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Clinical trials for LOCALLY RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new LOCALLY RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for LOCALLY RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo aims to outsmart tough cancers that resist standard treatment
Disease control Recruiting nowThis study is testing whether combining two drugs, cabozantinib and nivolumab, can help control advanced melanoma or head and neck cancer that has worsened despite standard immunotherapy. It will enroll about 150 adults whose cancer has progressed on prior treatment. A key goal i…
Matched conditions: LOCALLY RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
Blood pressure pill joins fight against tough head & neck cancers
Disease control Recruiting nowThis early-stage study is testing if a three-part treatment is safe and effective for people with head and neck cancer that has come back, spread a little, or hasn't responded to other treatments. The treatment combines a common blood pressure drug (losartan), an immunotherapy dr…
Matched conditions: LOCALLY RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: University of California, Davis • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
New hope for Tough-to-Treat head & neck cancers
Disease control Recruiting nowThis study is for people whose head and neck cancer has come back or never fully went away after initial treatment. It tests whether adding a short course of chemotherapy or chemotherapy plus an immunotherapy drug before a second surgery is better than surgery alone. The goal is …
Matched conditions: LOCALLY RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 18, 2026 14:40 UTC
-
New attack on tough head & neck cancers that come back
Disease control Recruiting nowThis early-stage trial is testing whether combining an immunotherapy drug called pembrolizumab with surgery and targeted radiation can better control head and neck cancers that have returned or didn't fully respond to previous treatments. The study aims to find the safest way to …
Matched conditions: LOCALLY RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Mar 02, 2026 15:24 UTC